-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $120 Price Target

Benzinga·09/02/2026 11:28:02
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $120 price target.